
Key Points
- 01Moderna aims to complete a U.S. filing for intismeran by year-end
- 02Intismeran is seen as a multibillion-dollar opportunity in oncology
- 03About 22,000 U.S. adjuvant melanoma patients may be eligible
- 04Marlborough site and Merck partnership underpin launch plans
Moderna targets year-end U.S. filing for intismeran
Moderna is preparing to complete a U.S. biologics license application for its individualized cancer therapy intismeran by year-end, following positive phase III melanoma data. The therapy, a personalized cancer vaccine, delivered a hazard ratio of 0.58 in the intent-to-treat population and 0.51 in the modified intent-to-treat group in the melanoma study. Management describes intismeran as a multibillion-dollar opportunity and says the company is commercially ready even though the product has not yet been approved.
Based on inclusion criteria from the phase III melanoma trial, Moderna estimates that 22,000 patients in the United States could be eligible for intismeran in the adjuvant melanoma setting. The company has not disclosed eligible patient populations for other potential indications but characterizes renal cell carcinoma, bladder cancer and lung cancer as additional multi-billion dollar opportunities.
Manufacturing build-out and operational readiness
To support intismeran, Moderna has developed a purpose-built facility in Marlborough that is currently operating one manufacturing suite. Management indicates this single suite should be sufficient for commercialization in melanoma, with plans to add up to six suites as demand grows and additional indications advance. At full build-out, the site is expected to supply tens of thousands of patients and support a global launch.
The company is focusing on ensuring treatment sites can obtain and submit appropriate tumor tissue for sequencing and manufacturing. In clinical trials, turnaround time was about 63 days, influenced partly by coordination with pembrolizumab infusion schedules. Moderna now sees around six weeks as achievable, with approximately 30 days reached in favorable circumstances, while manufacturing success in the clinical program exceeded 99%, with only one of more than 700 assigned patients unable to receive product.
Commercial model and Merck collaboration
Moderna’s partnership with Merck includes a 50-50 profit share on intismeran. The two companies plan to co‑market the therapy in the United States, while Merck will be responsible for commercialization outside the country. Moderna is still determining how to account for sales within this structure together with Merck and their auditors.
Pricing decisions for intismeran have not yet been finalized. Management indicated that the eventual price could span a range from levels comparable to pembrolizumab to the higher pricing typical of individualized cell therapies, with the final decision expected closer to launch. The company stated that its infectious disease vaccines business is expected to become profitable and fund its own programs, while an anticipated year‑end balance sheet of about $9 billion is intended to support oncology development.
Broader oncology pipeline and upcoming data
Beyond melanoma, Moderna and Merck are advancing trials of intismeran in renal cell carcinoma, bladder cancer and lung cancer. An interim efficacy analysis in renal cell carcinoma is expected within about the next 12 months, and final data from a randomized bladder cancer study are anticipated in 2027. A phase III lung cancer study that has completed enrollment could yield results in late 2027 or 2028, depending on when required events occur, and the company has two other phase III studies in the adjuvant lung cancer setting.
Moderna is also progressing other oncology and rare disease candidates, including myeloma data for its mRNA‑2808 T‑cell engager expected at the ASH meeting next month and a pivotal readout in propionic acidemia. Management emphasized that the next phase of its oncology strategy will depend on executing regulatory filings, expanding manufacturing capacity, securing further randomized data and refining its algorithms using results from ongoing trials.
Key Takeaways
- 01Moderna is moving quickly from positive phase III melanoma results toward a year-end U.S. filing, positioning intismeran as its lead oncology asset.
- 02Manufacturing capacity and logistics, including rapid turnaround from tissue collection to product, are central to scaling a personalized cancer therapy.
- 03The Merck partnership, profit‑sharing model and pending pricing decisions will shape the commercial profile as Moderna expands into multiple tumor types.
- 04A sizable addressable population in adjuvant melanoma and a robust late‑stage pipeline in kidney, bladder and lung cancer underpin Moderna’s multibillion‑dollar opportunity view.
- 05A strong balance sheet and expectations of profitability in infectious disease vaccines are intended to underwrite sustained investment in oncology development.
References
- https://www.marketbeat.com/instant-alerts/event-moderna-targets-year-end-cancer-therapy-filing-sees-multibillion-dollar-opportunity-2026-11-18/?.tsrc=rss
- https://ph.investing.com/news/stock-market-news/moderna-at-jefferies-global-healthcare-conference-oncology-push-builds-93CH-2707691
- https://br.investing.com/news/transcripts/moderna-inc-apresenta-estrategia-ambiciosa-em-oncologia-na-conferencia-jefferies-93CH-2131015